{"disease":{"id":"primary-biliary-cirrhosis","name":"Primary biliary cirrhosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"ursolvan","indication_name":"Primary biliary cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ursolvan","company_name":"Hopital Foch","drug_phase":"phase_3","molecular_target":"Aldo-keto reductase family 1 member C2, CDGSH iron-sulfur domain-containing protein 1, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ursodiol","indication_name":"Primary biliary cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actigall","generic_name":"URSODIOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 1","drug_class":"Bile Acid [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06519162","title":"Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Chungnam National University Hospital","has_results":false},{"nct_id":"NCT05786482","title":"Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":825,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03337074","title":"Paternally Inherited Phenotypes in Cholestasis","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT04526665","title":"Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":161,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT03668145","title":"Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Xijing Hospital of Digestive Diseases","has_results":false},{"nct_id":"NCT04278820","title":"A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04956328","title":"Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT02955602","title":"Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03941184","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03226067","title":"Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":true},{"nct_id":"NCT05374200","title":"Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC)","phase":"NA","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03743272","title":"Repeatability and Reproducibility of Multiparametric MRI","phase":"","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT03590886","title":"Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02609048","title":"Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03665519","title":"Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Scientific Medical Center, Kazakhstan","has_results":false},{"nct_id":"NCT03809559","title":"Repeatability and Reproducibility of Quantitative MRCP","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT03112681","title":"Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":true},{"nct_id":"NCT04791527","title":"Online Wellness Intervention for Primary Biliary Cholangitis (PBC)","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT01865812","title":"Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT04950764","title":"An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT04604652","title":"Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"HighTide Biopharma Pty Ltd","has_results":true},{"nct_id":"NCT04522869","title":"Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Vinmec Research Institute of Stem Cell and Gene Technology","has_results":false},{"nct_id":"NCT06525311","title":"A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Kowa Research Institute, Inc.","has_results":false},{"nct_id":"NCT03253276","title":"Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04047160","title":"Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Kiminori Kimura, MD","has_results":false},{"nct_id":"NCT03082937","title":"An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Albireo","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}